...
机译:用mRNA电穿孔的树突细胞接种诱导III期和IV黑色素瘤患者的稳健肿瘤抗原特异性CD4 +和CD8 + T细胞反应
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Medical Oncology Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Department of Hematology Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Department of Surgery Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Department of Dermatology Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Department of Pathology Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Deparment of Laboratory Medicine Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Radiology Radboud University Nijmegen Medical Centre Nijmegen Netherlands;
Laboratory of Molecular and Cellular Therapy Department of Physiology-Immunology Vrije;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
Department of Medical Oncology Academic Medical Centre Amsterdam Netherlands;
Department of Tumor Immunology Nijmegen Centre for Molecular Life Sciences PO Box 9101 6500 HB;
机译:用mRNA电穿孔的树突细胞接种诱导III期和IV黑色素瘤患者的稳健肿瘤抗原特异性CD4 +和CD8 + T细胞反应
机译:使用长NY-ESO-1 79-108肽和CpG-B进行疫苗接种可在III / IV期黑素瘤患者和新的HLA-DR7表位中强烈激活CD4和CD8 T细胞应答
机译:皮肤来源的肿瘤特异性T细胞在III期和IV期黑色素瘤患者的树突细胞疫苗接种研究中预测临床结果
机译:用PRRS病毒GP5蛋白脉冲树突细胞的免疫诱导CD4 +但不是CD8 + T细胞
机译:提供抗原特异性CD4 + T细胞可防止在前列腺癌的小鼠模型中耐受CD8 +肿瘤特异性T细胞。
机译:用长NY-ESO-1肽和CpG-B进行的III / IV期黑色素瘤患者的疫苗接种可产生具有多种特异性的强大CD8 +和CD4 + T细胞反应包括新的DR7限制性表位
机译:接种mRNA的树突状细胞疫苗可诱导III和IV期黑色素瘤患者的强大的肿瘤抗原特异性CD4(+)和CD8(+)T细胞反应。